

RECORDATI: PUBLIC DISCLOSURE COMPLIANCE

Milan, 27 March 2018 – Please be informed that the Report issued by the Board of Statutory Auditors on the financial statements as at 31 December 2017 and the Reports issued by the Independent Auditors on the financial statements as at 31 December 2017, on the consolidated financial statements as at 31 December 2017 and on the 2017 consolidated non-financial information disclosure pursuant to Legislative Decree n. 254 dated 30 December 2016 are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it; Section Investors, Shareholders' Meetings) and on the "1info" storage mechanism (www.1info.it).

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, other Central and Eastern European countries, Turkey, North Africa, the United States of America, Canada, Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: investorelations@recordati.it

Media Relations

Studio Noris Morano

(39)0276004736, (39)0276004745

e-mail: norismorano@studionorismorano.com